94 related articles for article (PubMed ID: 21574905)
1. Economic impact of potential drug-drug interactions in opioid analgesics.
Summers KH; Puenpatom RA; Rajan N; Ben-Joseph R; Ohsfeldt R
J Med Econ; 2011; 14(4):390-6. PubMed ID: 21574905
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids.
Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Ben-Joseph R; Ohsfeldt R; Summers KH
Pain Pract; 2012 Jan; 12(1):33-44. PubMed ID: 21951824
[TBL] [Abstract][Full Text] [Related]
3. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions.
Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Joo S; Ben-Joseph R; Summers KH
Pain Pract; 2011; 11(4):325-36. PubMed ID: 21199317
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids.
Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Joo S; Ben-Joseph RH; Summers KH
Pain Pract; 2011; 11(3):230-9. PubMed ID: 20807350
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids.
Pergolizzi JV; Labhsetwar SA; Amy Puenpatom R; Ben-Joseph R; Ohsfeldt R; Summers KH
Pain Pract; 2012 Jan; 12(1):45-56. PubMed ID: 21923882
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the impact of drug-drug interactions associated with opioids.
Pergolizzi JV
Am J Manag Care; 2011 Sep; 17 Suppl 11():S288-92. PubMed ID: 21999761
[TBL] [Abstract][Full Text] [Related]
7. Opioid pharmacokinetic drug-drug interactions.
Overholser BR; Foster DR
Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
[TBL] [Abstract][Full Text] [Related]
8. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
Kwong WJ; Diels J; Kavanagh S
Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
[TBL] [Abstract][Full Text] [Related]
9. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs and nonadherence among chronic opioid users.
Leider HL; Dhaliwal J; Davis EJ; Kulakodlu M; Buikema AR
Am J Manag Care; 2011 Jan; 17(1):32-40. PubMed ID: 21348566
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
12. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
13. Financial and clinical characteristics of fibromyalgia: a case-control comparison.
Palacio A; Uribe CL; Li H; Hanna J; Deminski M; Alvir J; Chandran A; Sanchez R
Am J Manag Care; 2010 May; 16(5 Suppl):S118-25. PubMed ID: 20586520
[TBL] [Abstract][Full Text] [Related]
14. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia.
Berger A; Sadosky A; Dukes EM; Edelsberg J; Zlateva G; Oster G
Am J Manag Care; 2010 May; 16(5 Suppl):S126-37. PubMed ID: 20586521
[TBL] [Abstract][Full Text] [Related]
15. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation.
Iyer S; Davis KL; Candrilli S
Manag Care; 2010 Mar; 19(3):44-51. PubMed ID: 20361548
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.
Pergolizzi JV; Ma L; Foster DR; Overholser BR; Sowinski KM; Taylor R; Summers KH
J Manag Care Spec Pharm; 2014 May; 20(5):467-76. PubMed ID: 24761818
[TBL] [Abstract][Full Text] [Related]
17. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
19. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy.
Candrilli SD; Davis KL; Iyer S
J Pain Palliat Care Pharmacother; 2009; 23(3):231-41. PubMed ID: 19670020
[TBL] [Abstract][Full Text] [Related]
20. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
